Hostname: page-component-848d4c4894-pjpqr Total loading time: 0 Render date: 2024-06-21T01:00:23.940Z Has data issue: false hasContentIssue false
  • English
  • Français

Correlation between plasma levels of prolactin and chlorpromazine in psychiatric patients1

Published online by Cambridge University Press:  09 July 2009

T. Kolakowska ,
D. H. Wiles ,
A. S. McNeilly  and
M. G. Gelder
T. Kolakowska
Affiliation:
Department of Psychiatry, University of Oxford, Department of Chemical Pathology, St. Bartholomew's Hospital, London
D. H. Wiles
Affiliation:
Department of Psychiatry, University of Oxford, Department of Chemical Pathology, St. Bartholomew's Hospital, London
A. S. McNeilly
Affiliation:
Department of Psychiatry, University of Oxford, Department of Chemical Pathology, St. Bartholomew's Hospital, London
M. G. Gelder*
Affiliation:
Department of Psychiatry, University of Oxford, Department of Chemical Pathology, St. Bartholomew's Hospital, London
*
2Address for correspondence: Professor M. G. Gelder, Department of Psychiatry, The Warneford Hospital, Oxford OX3 7JX.
Get access Rights & Permissions [Opens in a new window]

Synopsis

Plasma levels of chlorpromazine (CPZ) and prolactin were measured repeatedly in 14 psychiatric patients throughout CPZ treatment. Mean prolactin level was elevated in 11 subjects (all six women and five of eight men). Mean plasma prolactin correlated significantly with mean plasma CPZ but not with the dose of the drug. Only patients with mean plasma prolactin above 35 ng/ml developed Parkinsonian side-effects.

Type
Preliminary Communication
Information
Psychological Medicine , Volume 5 , Issue 2 , May 1975 , pp. 214 - 216
Copyright
Copyright © Cambridge University Press 1975

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

1

This work was supported by grants from the Medical Research Council and the Oxford Regional Hospital Board.

References

Beumont, P. J. V., Corker, C. S., Friesen, H. G., Kolakowska, T., Mandelbrote, B. M., Marshall, J., Murray, M. A. F., and Wiles, D. H. (1974). The effects of phenothiazines on endocrine function: 2. British Journal of Psvchiatry, 124, 420–430.Google Scholar
Curry, S. H. (1968). Determination of nanogram quantities of chlorpromazine and some of its metabolites using gas liquid chromatography with an electron capture detector. Analytical Chemistry, 40, 1251–1255.Google Scholar
De Wied, D., and De Jong, W. (1974). Drug effects and hypothalamic-anterior pituitary function. Annual Review of Pharmacologv, 14, 389–412.CrossRefGoogle Scholar
Frantz, A. G., Kleinberg, D. L., and Noel, G. L. (1972). Physiological and pathological secretion of human prolactin studied by in vitro bioassay. In Lactogenic Hormones, pp. 137–150. Edited by Wolstenholme, G. E. W. and Knight, J.. Churchill Livingstone: Edinburgh.Google Scholar
Friesen, H. G., Guyda, H., Hwang, P., Tyson, J. E., and Barbeau, A. (1972). Functional evaluation of prolactin secretion: a guide to therapy. Journal of Clinical Investigation, 51, 706–709.Google Scholar
Kleinberg, D. L., Noel, L. G., and Frantz, A. G. (1971). Chlorpromazine stimulation and I-dopa suppression of plasma prolactin in man. Journal of Clinical Endocrinology and Metabolism, 33, 873–875.CrossRefGoogle Scholar
MacKay, A. V. P., Healey, A. F., and Baker, J. (1974). The relationship of plasma chlorpromazine to its 7-hydroxy and sulphoxide metabolites in a large population of schizophrenics. British Journal of Clinical Pharmacology, 1, 425–430.Google Scholar
McNeilly, A. S., and Hagen, C. (1974). Prolactin, TSH, LH and FSH responses to a combined LHRH/TRH test at different stages of the menstrual cycle. Clinical Endocrinology, 3, 427–435.Google Scholar
Overall, G. E., and Gorkham, D. R. (1962). The brief psychiatric rating scale. Psychological Reports, 10, 799.Google Scholar
Simpson, G. N., and Angus, J. W. S. (1970). A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavka. Suppl. 212.Google Scholar